Showing 3961-3970 of 8129 results for "".
- Risk-Guided Screening Enhances Early Skin Cancer ID in Transplant Cohorthttps://practicaldermatology.com/news/risk-guided-screening-enhances-early-skin-cancer-id-in-transplant-cohort/2483972/A risk-based skin cancer surveillance strategy was associated with improved early detection rates among solid organ transplant (SOT) recipients, according to findings from a recent retrospective cohort analysis of the implementation of the KP-SUNTRAC program across K
- Dr. Andrew Alexis Highlights 2-MNG as Option to Treat Acne-Related PIHhttps://practicaldermatology.com/news/dr-andrew-alexis-highlights-2-mng-as-option-to-treat-acne-related-pih/2483902/The topical agent 2-Mercaptonicotinoyl glycine (2-MNG), also marketed as Melasyl, could be key to treating acne-related postinflammatory hyperpigmentation (PIH) in skin of color, Andrew Alexis, MD, MPH, said at the Skin of Color Update in New York, New York. Dr. Alexis presented on managin
- FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCChttps://practicaldermatology.com/news/fda-approves-libtayo-for-adjuvant-treatment-of-high-risk-cscc/2483899/The FDA has approved cemiplimab-rwlc (Libtayo, Regeneron) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence following surgery and radiation, according to a statement from the agency.
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia
- Latino Melanoma Patients Face Barriers to Early Diagnosis and Treatmenthttps://practicaldermatology.com/news/latino-melanoma-patients-face-barriers-to-early-diagnosis-and-treatment/2483846/A new qualitative study published in JAMA Dermatology explored persistent disparities Latino patients face in timely melanoma diagnosis and treatment, despite advances in therapy that have improved survival among non-Hispani
- Study: Ruxolitinib Cream Same or Better Than Triamcinolone for Mild to Moderate ADhttps://practicaldermatology.com/news/ruxolitinib-cream-triamcinolone-for-mild-to-moderate-ad/2483574/New analysis of phase 2 data indicates ruxolitinib cream 1.5% may offer comparable or superior efficacy to midpotency corticosteroid triamcinolone 0.1% cream in adult patients with long-standing mild to moderate atopic dermatitis (AD).
- Roflumilast Phase 2 Results for Children Consistent With Phase 3 Adult Trialshttps://practicaldermatology.com/news/roflumilast-phase-2-results-for-children-consistent-with-phase-3-adult-trials/2483558/Once-daily roflumilast cream 0.3% was well tolerated and improved signs and symptoms of psoriasis in children 2 to 11 years old in two 4-week, phase 2, open-label, maximal usage pharmacokinetic and safety studies, according to an article published in Pediatric Dermatology. The res
- Study Quantifies Cutaneous Reaction Risks of Some CKD Treatmentshttps://practicaldermatology.com/news/study-quantifies-cutaneous-reaction-risks-of-some-ckd-treatments/2483518/A newly validated risk prediction model in The Lancet Rheumatology could assist practitioners in estimating a patient’s short-term risk of developing severe cutaneous adverse reactions (SCARs) following initiation of allopuri
- From EADV: Povorcitinib Maintains Efficacy Through 24 Weeks in STOP-HS Programhttps://practicaldermatology.com/news/from-eadv-povorcitinib-maintains-efficacy-through-24-weeks-in-hs-phase-3-data/2483429/New 24-week results from the phase 3 STOP-HS trial program suggest that investigational oral JAK1 inhibitor povorcitinib provided sustained clinical benefits in adults with moderate to severe hidradenitis suppurativa (HS), according to findings presented at the 2025
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://practicaldermatology.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate